• Mon espace de travail
  • Aide IRIS
  • Par Publication Par Personne Par Unité
    • English
    • Français
  • Se connecter
Logo du site

IRIS | Système d’Information de la Recherche Institutionnelle

  • Accueil
  • Personnes
  • Publications
  • Unités
  • Périodiques
UNIL
  • English
  • Français
Se connecter
IRIS
  • Accueil
  • Personnes
  • Publications
  • Unités
  • Périodiques
  • Mon espace de travail
  • Aide IRIS

Parcourir IRIS

  • Par Publication
  • Par Personne
  • Par Unité
  1. Accueil
  2. IRIS
  3. Publication
  4. Effect of raloxifene and clodronate on bone density in postmenopausal osteoporotic women.
 
  • Détails
Titre

Effect of raloxifene and clodronate on bone density in postmenopausal osteoporotic women.

Type
article
Institution
Externe
Périodique
International journal of tissue reactions
Auteur(s)
D'Amelio, P.
Auteure/Auteur
Muratore, M.
Auteure/Auteur
Tinelli, F.
Auteure/Auteur
Tamone, C.
Auteure/Auteur
Cosentino, L.
Auteure/Auteur
Quarta, E.
Auteure/Auteur
Calcagnile, F.
Auteure/Auteur
Carlo Isaia, G.
Auteure/Auteur
Liens vers les personnes
D'Amelio, Patrizia  
ISSN
0250-0868
Statut éditorial
Publié
Date de publication
2003
Volume
25
Numéro
2
Première page
73
Dernière page/numéro d’article
78
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Clinical Trial ; Journal Article ; Randomized Controlled Trial
Publication Status: ppublish
Résumé
The aim of the present study was to determine the safety and efficacy of combined therapy with raloxifene (RLX) and clodronate (CLD) in postmenopausal women. We enrolled 45 women with postmenopausal osteoporosis. The patients were randomly assigned to two different therapeutic groups: RLX 60 mg/day (n = 23) and RLX 60 mg/day plus CLD 100 mg intramuscularly (i.m.) once every 10 days (n = 22); 1 g of calcium and 800 IU of vitamin D3 were also given daily to both groups. Lumbar and femoral bone mineral density (BMD) were assessed at baseline and after 12 months of therapy using the dual X-ray absorptiometry technique (Norland XR36). We measured the bone turnover markers NTx and CTx, bone alkaline phosphatase (BAP) and osteocalcin at baseline and after 12 months of therapy. Our data demonstrate that 1 year of combined RLX+CLD therapy induced a higher increase in lumbar BMD than treatment with RLX alone as well as a major decrease in bone resorption markers, suggesting an additive effect of CLD on bone mass and inhibition of bone turnover. Furthermore, after 1 year of therapy levels of bone formation markers (osteocalcin and BAP) had increased in both groups, but the increase in osteocalcin and BAP was significantly higher in the RLX+CLD treated group, suggesting that, in addition to its inhibitory effects on resorption, CLD might also have stimulatory effects on mature osteoblast activity.
Sujets

Absorptiometry, Photo...

Aged

Biomarkers/blood

Bone Density/drug eff...

Bone Remodeling/drug ...

Bone Remodeling/physi...

Bone Resorption/drug ...

Bone Resorption/physi...

Cholecalciferol/pharm...

Clodronic Acid/admini...

Clodronic Acid/advers...

Clodronic Acid/therap...

Female

Humans

Middle Aged

Osteoporosis, Postmen...

Osteoporosis, Postmen...

Raloxifene Hydrochlor...

Raloxifene Hydrochlor...

Raloxifene Hydrochlor...

Selective Estrogen Re...

Selective Estrogen Re...

PID Serval
serval:BIB_9116133B3006
PMID
14518596
WOS
000185566600006
Permalien
https://iris.unil.ch/handle/iris/213783
Date de création
2020-01-23T13:44:17.270Z
Date de création dans IRIS
2025-05-21T03:42:47Z
  • Copyright © 2024 UNIL
  • Informations légales